Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Clade Therapeutics Inc.
Headquarters: Cambridge, Massachusetts, United States of America
Website: https://cladetx.com
Year Founded: 2020
Status: Private
See Emerging Company Profile .
BioCentury | Oct 24, 2024
Management Tracks
Junaid Bajwa joins Flagship as senior partner, head of U.K.
Plus: Promotions at Citigroup and updates from FDA’s CDRH, LigaChem, Alphina, Kenai and Precision Medicine
BioCentury | Sep 26, 2024
Management Tracks
Century names CFO, CSO
Plus: Freenome’s CEO Nolan resigns and updates from NextRNA and Abiologics
BioCentury | Apr 16, 2024
Deals
Deals report: Vertex’s biggest deal yet, and more
Novartis gets two androgen receptor protein degraders from Arvinas and Genentech-Adaptimmune terminate allogeneic T cell therapy deal
BioCentury | Apr 12, 2024
Finance
Public equity report: Acrivon refreshes balance sheet with $130M PIPE
Plus Eliem, Century raise private placements as they make acquisitions; Nurix’s AACR readout precedes follow-on; Skye uplists
BioCentury | Nov 17, 2023
Management Tracks
Memo names Erik van den Berg as CEO
Plus: Martin Murphy stepping down as Syncona chair, and updates from Red Tree, OMass and Anagenex
BioCentury | Mar 24, 2023
Product Development
Landscape of emerging T cell therapies in cancer
Four axes of risk map how companies founded in the last five years are innovating in CAR T and TCR T cells
BioCentury | Mar 12, 2022
Management Tracks
BlueRock, Vertex vet Hei becomes CTO at Clade
Plus Saywell joins Herophilus as CBO, updates from VeriSIM and Sheppard Mullin
BioCentury | Feb 12, 2022
Emerging Company Profile
BioCentury’s 2021 class of emerging cell therapy companies
The 19 newcos are pushing the modality’s frontiers: tapping new cell types, reaching beyond blood cancers and rethinking manufacturing
BioCentury | Dec 22, 2021
Emerging Company Profile
Clade: immune-cloaked, iPSC-derived cell therapies
Syncona’s first allogeneic cell therapy investment goes to Clade, led by Sana and CRISPR Therapeutics co-founder Cowan
BioCentury | Nov 4, 2021
Data Byte
Five newcos developing iPS cell-derived therapies for cancer
The biotechs are turning iPS cells into NK, T, B cells and macrophages
Items per page:
1 - 10 of 10